The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells

  • Authors:
    • Jaejun Shim
    • Byung-Ho Kim
    • Young Il Kim
    • Kyung Yup Kim
    • Young Hwangbo
    • Jae Young Jang
    • Seok Ho Dong
    • Hyo Jong Kim
    • Young Woon Chang
    • Rin Chang
  • View Affiliations

  • Published online on: January 1, 2010     https://doi.org/10.3892/ijo_00000493
  • Pages: 223-231
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic hepatitis B virus (HBV) infection is the most common cause of hepatocellular carcinoma (HCC) worldwide. This study investigated the antineoplastic effects of intrinsic and extrinsic peroxisome proliferator-activated receptor γ (PPARγ) ligands against HBV-associated HCC cells in vitro. Four cell lines that were established from patients with HBV-associated HCC were used. The cells were cultured in various concentrations of the following PPARγ ligands: troglitazone, pioglitazone, rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2). Cell proliferation, cell cycle and apoptosis were analyzed. PPARγ was expressed in all the cell lines studied. Among the PPARγ ligands, pioglitazone and 15d-PGJ2 clearly inhibited the HBV-associated HCC cell growth and increased the proportion of cells in the sub-G1 phase in the cell-cycle analysis. In apoptosis assays, DNA fragments increased significantly, and the activities of caspase-3 and -9 also increased. A pan-caspase inhibitor and a caspase-3 inhibitor suppressed the PPARγ ligand-induced apoptosis in a dose-dependent manner. These two PPARγ ligands decreased the expression of bcl-2 in most of the cell lines studied. The results suggest that pioglitazone and 15d-PGJ2 have antineoplastic effects on HBV-associated HCC cells. Both of these PPARγ ligands could be candidates for cancer prevention or the chemotherapy of HBV-associated HCC.

Related Articles

Journal Cover

January 2010
Volume 36 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shim, J., Kim, B., Kim, Y.I., Kim, K.Y., Hwangbo, Y., Jang, J.Y. ... Chang, R. (2010). The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. International Journal of Oncology, 36, 223-231. https://doi.org/10.3892/ijo_00000493
MLA
Shim, J., Kim, B., Kim, Y. I., Kim, K. Y., Hwangbo, Y., Jang, J. Y., Dong, S. H., Kim, H. J., Chang, Y. W., Chang, R."The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells". International Journal of Oncology 36.1 (2010): 223-231.
Chicago
Shim, J., Kim, B., Kim, Y. I., Kim, K. Y., Hwangbo, Y., Jang, J. Y., Dong, S. H., Kim, H. J., Chang, Y. W., Chang, R."The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells". International Journal of Oncology 36, no. 1 (2010): 223-231. https://doi.org/10.3892/ijo_00000493